BRIEF-AbbVie reports positive Phase 2 data for ibrutinib in cGVHD patients

* Late-Breaking ibrutinib (imbruvica) data show complete or partial response in two-thirds of patients with chronic graft-versus-host-disease, a frequent and potentially life-threatening complication of stem cell transplant